Emcure Pharmaceuticals (BSE:544210, NSE: EMCURE) has announced its unaudited consolidated financial results for the quarter ending June 30, 2024, showcasing strong performance across various markets. The company reported a 17% growth in revenue and a 16% increase in EBITDA, reflecting robust business momentum.
In India, which contributes 50% of the company’s total revenue, Emcure achieved a 14% growth, bringing in ₹909 crore. This growth was driven by solid performance in its core business and boosted by a distribution partnership with Sanofi for its cardiovascular brands. The integration of Sanofi’s portfolio into Emcure’s chronic care segment has met the company’s expectations, contributing to its domestic success.
Internationally, Emcure’s European operations grew by 8.6%, supported by an increase in market share for its core products. In Canada, Emcure’s subsidiaries, Marcan and Mantra, are experiencing strong growth, reinforcing Emcure’s position as one of the top 10 generic pharmaceutical players in the Canadian market. The company also reported continued traction in key focus markets within the Rest of World (RoW) category.
CEO and Managing Director Satish Mehta commented on the results, stating, “Emcure delivered a solid performance in Q1, reflecting the positive impact of our investments in both domestic and international markets. Our recent acquisitions—Sanofi in India and Mantra in Canada—are now fully integrated, and our strategy moving forward will focus on expanding our presence in India and accelerating product launches internationally to sustain strong growth.”
Emcure Pharmaceuticals Ltd., headquartered in Pune, is a leading Indian pharmaceutical company involved in the development, manufacturing, and global marketing of a diverse range of pharmaceutical products. Known for its innovation and commitment to quality, Emcure focuses on creating patient-centric solutions across various therapeutic areas.
Founded in 1981, Emcure ranks as the 12th largest pharmaceutical company in India based on Domestic Sales as of June 2024. The company has a presence in over 70 countries, including key markets in Europe and Canada.
